PTC/SB/088 (10-01)Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under-Ito Pa Paperwork-Reduction-Act-of-1995; no-persons are required to respond to a collection of information unless it contains a velid OMB

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Sheet

Application Number 09/970,558 **Filing Date** October 4, 2001 **First Named Inventor** David A. Carver **Group Art Unit** 1614 **Examiner Name** Dwayne C. Jones **Attorney Docket Number** NPB-100D5

Complete if Known

Examiner No. Include name of the author (in CAPITAL LETTERS), title of the article, when appropriately life of the intended in the article, when appropriately life of the intended in the intended intended intended in the intended intended intended in the intended i			NON PATENT LITERATURE DOCUMENTS	
with copies of references cited therein. Second Affidavit of Prof. Siegfried Blechert; opinion concerning related Israeli patent in support of the opposition filed by Teva Pharmaceuticals Industries Ltd. R3 R4 R5 R6 R7 R8 R9 R10 R11 R12		Cite No. '	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
patent in support of the opposition filed by Teva Pharmaceuticals Industries Ltd. R3 R4 R5 R6 R7 R8 R9 R10 R11 R12	M.	R1	Opponent's Response to the Appeal dated September 12, 2003 in the EPO, along with copies of references cited therein.	
R4 R5 R6 R7 R8 R8 R9 R10 R11 R12		R2	Second Affidavit of Prof. Siegfried Blechert; opinion concerning related Israeli patent in support of the opposition filed by Teva Pharmaceuticals Industries Ltd.	
R5 R6 R7 R8 R8 R9 R10 R11 R12	<u></u>	R3		
R6 R7 R8 R9 R10 R11 R12	•	R4	RECEIVE	
R8 R9 R10 R11 R12		R5	NOV 0 6 200	
R8 R9 R10 R11 R12		R6		2000
R9 R10 R11 R12		R7	TECH CENTER 1000	284
R10 R11 R12		R8		
R11 R12	· .	R9		
R12		R10		
		R11		
R13		R12		
		R13		

	 <u> </u>	1		 	 		1	Ĺ	ł	
Examiner Signature	Ura	Ine o	tores		 Date Considered	Â	4	\$	04	
	1-4-7	$\Lambda = 7$				O.		- 7		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation of umber (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.